Results 31 to 40 of about 453,940 (280)

Monoaminergic Neuropathology in Alzheimer's disease [PDF]

, 2016
Acknowledgments This work was supported by The Croatian Science Foundation grant. no. IP-2014-09-9730 (“Tau protein hyperphosphorylation, aggregation, and trans-synaptic transfer in Alzheimer’s disease: cerebrospinal fluid analysis and assessment of ...
Bažadona, Danira, Buée, Luc, Delalle, Ivana, Giovanni, Giuseppe Di, Harrington, Charles R., Hof, Patrick R., Jovanov-Milošević, Nataša, Leko, Mirjana Babić, Silva, Rohan de, Wischik, Claude M., Wray, Selina, Šimić, Goran   +11 more
core   +1 more source

Neurodegeneration: Potential Causes, Prevention, and Future Treatment Options [PDF]

, 2011
Here I advance a hypothesis that neurodegeneration is a natural process associated with aging due to the loss of genetic redundancy following a mathematical model R(t) = R0(1-αe(βC+γI+δEt)t), where the calorie intake (C) and ...
Zhongtao Zhang
core   +2 more sources

Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer\u27s disease [PDF]

, 2019
Interest in understanding the roles of white matter (WM) inflammation and damage in the pathophysiology of Alzheimer disease (AD) has been growing significantly in recent years.
Ances, Beau M, Benzinger, Tammie L.S., Blazey, Tyler, Cairns, Nigel J, Chen, Charlie, Cruchaga, Carlos, Fagan, Anne M, Gordon, Brian A, Liu, Jingxia, Morris, John C, Shimony, Joshua S, Su, Yi, Sutphen, Courtney L, Wang, Qing, Wang, Yong   +14 more
core   +2 more sources

Forecasting the progression of Alzheimer's disease using neural networks and a novel preprocessing algorithm

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019
Introduction There is a 99.6% failure rate of clinical trials for drugs to treat Alzheimer's disease, likely because Alzheimer's disease (AD) patients cannot be easily identified at early stages. This study investigated machine learning approaches to use
Jack Albright, Alzheimer's Disease Neuroimaging Initiative   +1 more
doaj   +1 more source

Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment

NeuroImage: Clinical, 2019
NIA-AA diagnostic criteria include volumetric or visual rating measures of hippocampal atrophy (HA) as a diagnostic biomarker of Alzheimer's disease (AD).
Neus Falgàs, Raquel Sánchez-Valle, Núria Bargalló, Mircea Balasa, Guadalupe Fernández-Villullas, Beatriz Bosch, Jaume Olives, Adrià Tort-Merino, Anna Antonell, Cristina Muñoz-García, María León, Oriol Grau, Magdalena Castellví, Nina Coll-Padrós, Lorena Rami, Alberto Redolfi, Albert Lladó   +16 more
doaj   +1 more source

Validation of machine learning models to detect amyloid pathologies across institutions. [PDF]

, 2020
Semi-quantitative scoring schemes like the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) are the most commonly used method in Alzheimer's disease (AD) neuropathology practice.
Dugger, Brittany N, Gearing, Marla, Glass, Jonathan D, Gutman, David A, Keiser, Michael J, Vizcarra, Juan C   +5 more
core  

The role of the Amyloid Precursor Protein mutations and PERK-dependent signaling pathways in the pathogenesis of Alzheimer’s disease [PDF]

, 2016
Alzheimer’s disease (AD) is a highly complex, progressive, age-related neurodegenerative human disease entity. The genetic basis of AD is strictly connected with occurrence of mutations in Amyloid Precursor (APP) gene on chromosome 21.
Diehl, J. Alan, Lewko, Dawid, Majsterek, Ireneusz, Nowak, Alicja, Pytel, Dariusz, Rozpędek, Wioletta   +5 more
core   +2 more sources

Sex and ethnicity in early‐onset Alzheimer's disease biomarkers and global function

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Early‐onset Alzheimer's disease (EOAD) may have distinct biomarker and clinical features from late‐onset AD (LOAD). EOAD is understudied in ethnically heterogeneous populations. METHODS We studied EOAD (N = 44, age 64.7 ± 5.5, 55% female, 52%
Breton M. Asken, Wei‐En Wang, Franchesca Arias, Shellie‐Anne Levy, Warren W. Barker, Monica Rosselli, Rosie Curiel Cid, Michael Marsiske, Melissa J. Armstrong, David E. Vaillancourt, David A. Loewenstein, Glenn E. Smith, Ranjan Duara   +12 more
doaj   +1 more source

Brain transcriptomes of zebrafish and mouse Alzheimer's disease knock-in models imply early disrupted energy metabolism

Disease Models & Mechanisms, 2022
Energy production is the most fundamentally important cellular activity supporting all other functions, particularly in highly active organs, such as brains.
Karissa Barthelson, Morgan Newman, Michael Lardelli   +2 more
doaj   +1 more source

Altered Expression of the CB1 Cannabinoid Receptor in the Triple Transgenic Mouse Model of Alzheimer's Disease [PDF]

, 2014
The endocannabinoid system has gained much attention as a new potential pharmacotherapeutic target in various neurodegenerative diseases, including Alzheimer's disease (AD).
*EQUAL CONTRIBUTION, Adele Romano*, Angelo Michele Lavecchia, Caterina Grillo, F.m. Laferla, Fabio Altieri, Gaurav Bedse*, Gianluigi Vendemiale, Lorenzo Federico Pace, M.r. Elphick, Silvana Gaetani, Silvia Cianci, Tommaso Cassano   +12 more
core   +1 more source